Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has not yet been able to achieve good long-term survival. The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers, including non-small cell lung cancer (NSCLC). Nivolumab is the PD-1 inhibitor approved for the treatment of NSCLC to show a survival benefit in a randomised phase III trials. The experience of physicians in routine clinical practice is often different from those in a controlled clinical trial setting. The purpose of this analysis is to evaluate nivolumab use in real world setting. Results: The general survival at 76 patients by metastatic NSLC receiving an immunotherapy nivolumab during the period from 2015 to 2019 is analysed. The minimum time of observation was 1.6 months. The median of the general survival made 7.6 months (5.92-9.41. DI 95%). The one-year survival - 35%, at the same time 3-year survival was 25%. At patients with the objective answer the median of the general survival was not reached. Immunomediated adverse events developed in 42% of patients, but only 6.6% showed the development of adverse events of 3-4 degrees, which indicates a favorable toxicity profile. Conclusion: the results received by us correlate with data of clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
